SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Advanced Micro Devices, Inc. engages in the semiconductor business. Its products include processors, accelerators, graphics, adaptive SoCs, FPGAs, and SOMs, and software, tools, and apps. The firm offers artificial intelligence, industries, workloads, and gaming solutions. The company was founded by W. J. Sanders III on May 1, 1969 and is headquartered in Santa Clara, CA.

Advanced Micro Devices Inc.

Advanced Micro Devices Inc

AMD is trending amidst a robust multi-year deal to supply AI chips to Meta Platforms, signaling the company's strong position in the diversifying AI infrastructure market. The community is actively discussing AMD's competitive advantage and strategic investments like the Crusoe loan, reinforcing its role as a key player in powering future AI growth.

Cipher Mining, Inc. operates as a Bitcoin mining ecosystem in the United States. The firm is developing a cryptocurrency business. The company was founded in 2021 and is headquartered in New York, NY.

Cipher Mining Inc

Cipher Mining is trending as its strategic pivot to an AI/HPC data center development company gains significant market attention, underscored by its rebrand to Cipher Digital and a major sale of Bitcoin mining assets. The community is actively discussing its undervalued status and potential rerating as stable, long-term contracts with hyperscale customers position it for future growth, despite short-term volatility.

NVIDIA Corp. engages in the design and manufacture of computer graphics processors, chipsets, and related multimedia software. It operates through the following segments: Graphics Processing Unit (GPU) and Compute & Networking. The Graphics segment includes GeForce GPUs for gaming and PCs, the GeForce NOW game streaming service and related infrastructure, Quadro and NVIDIA RTX GPUs for enterprise workstation graphics, virtual GPU, or vGPU, software for cloud-based visual and virtual computing, automotive platforms for infotainment systems, and Omniverse Enterprise software for building and operating metaverse and 3D internet applications. The Compute & Networking segment consists of Data Center accelerated computing platforms and end-to-end networking platforms including Quantum for InfiniBand and Spectrum for Ethernet, NVIDIA DRIVE automated-driving platform and automotive development agreements, Jetson robotics and other embedded platforms, NVIDIA AI Enterprise and other software, and DGX Cloud software and services. The company was founded by Jen Hsun Huang, Chris A. Malachowsky, and Curtis R. Priem in April 1993 and is headquartered in Santa Clara, CA.

NVIDIA Corp

NVIDIA is actively trending ahead of its highly anticipated earnings report, with significant community debate around continued insatiable AI chip demand and a potentially sold-out product pipeline, contrasted by some investors anticipating a 'sell the news' reaction and observing rising competition.

Meta Platforms, Inc. engages in the development of social media applications. It builds technology that helps people connect and share, find communities, and grow businesses. It operates through the Family of Apps (FoA) and Reality Labs (RL) segments. The FoA segment consists of Facebook, Instagram, Messenger, WhatsApp, and other services. The RL segment includes augmented, mixed and virtual reality related consumer hardware, software, and content. The company was founded by Mark Elliot Zuckerberg, Dustin Moskovitz, Chris R. Hughes, Andrew McCollum, and Eduardo P. Saverin on February 4, 2004, and is headquartered in Menlo Park, CA.

Meta Platforms Inc - Ordinary Shares - Class A

Meta Platforms Inc

Meta is actively discussed following news of significant multi-year agreements with both Nvidia and AMD for AI chips; bulls view these massive investments as a strategic move to dominate the AI landscape, while bears express concern over escalating capital expenditures impacting profitability amid market volatility and ongoing regulatory scrutiny.

Vir Biotechnology, Inc. operates as a clinical-stage immunology company that focuses on combining immunologic insights with cutting-edge technologies to treat and prevent serious infectious diseases. The firm's technology platforms include antibody, T cell, innate immunity and siRNA, which are designed to stimulate and enhance the immune system by exploiting critical observations of natural immune processes. The company was founded by Robert Taylor Nelsen, Klaus Frueh, Jay Parrish, Lawrence Corey, and Louis Picker in April 7, 2016 and is headquartered in San Francisco, CA.

Vir Biotechnology Inc

Vir Biotechnology is trending following its recent corporate update and strong financial results, highlighted by a major global collaboration with Astellas for its VIR-5500 prostate cancer program, which includes substantial upfront payments and significant milestone potential. Community discussion is actively debating the new cash influx, promising early clinical data, and potential for a short squeeze, while others predict a 'rug pull' based on the stock's historical tendency for gains to reverse.

ImmunityBio, Inc. is a clinical stage immunotherapy company. It develops next generation therapies that drive immunogenic mechanisms for defeating cancers and infectious diseases. The company's immunotherapy platform activates both the innate and adaptive immune systems to create long term immunological memory. ImmunityBio was founded by Patrick Soon-Shiong in 2014 and is headquartered in San Diego, CA.

ImmunityBio Inc

ImmunityBio is generating significant buzz following robust revenue growth for ANKTIVA and an ambitious plan to expand its BioShield platform across multiple cancer indications and global markets. The community is actively discussing the potential for a substantial short squeeze, propelled by strong bullish sentiment and anticipation of further positive catalysts.

DigitalOcean Holdings, Inc. engages in the provision of providing cloud infrastructure. It operates through the following geographical segments: United States, Netherlands, Germany, Canada, Singapore, and Other. The company was founded in 2012 and is headquartered in Broomfield, CO.

DigitalOcean Holdings Inc

DigitalOcean is trending as investors react to its latest earnings report, which showcased accelerating revenue growth guidance for 2026 and 2027, robust expansion in AI workloads, and a successful shift towards larger enterprise customers. The community is actively discussing DOCN's enhanced position as a crucial AI inference and cloud infrastructure provider, fueling a strong re-evaluation of its growth trajectory.

The AES Corp. engages in the provision of power generation and utility services through its renewable and thermal generation facilities and distribution businesses. It operates through the following segments: U.S. and Utilities Strategic Business Unit (SBU), South America SBU, MCAC SBU, Eurasia SBU. The U.S. and Utilities SBU segment consists of facilities in the United States, Puerto Rico and El Salvador. The South America SBU segment covers Chile, Colombia, Argentina, and Brazil. The MCAC SBU segment refers to Mexico, Central America, and the Caribbean. The Eurasia SBU segment handles operations in Europe and Asia. The company was founded by Dennis W. Bakke and Roger W. Sant in 1981 and is headquartered in Arlington, VA.

AES Corp.

AES Corporation is trending amid widespread reports that BlackRock's Global Infrastructure Partners is nearing a multi-billion-dollar takeover, a move seen to capitalize on the utility's strategic position in supplying renewable energy to fast-growing tech and AI data centers. The community is intensely debating the potential acquisition price, weighing the company's significant debt against its long-term growth prospects and perceived undervaluation.

GraniteShares ETF Trust - GraniteShares 2x Long AMD Daily ETF

GraniteShares 2x Long AMD Daily ETF

AMDL is gaining attention due to positive developments for its underlying AMD, including a $1 billion Department of Energy partnership, an export license for AI chips to China, and an analyst upgrade citing sold-out server chips for 2026. The community is keenly discussing whether recent pullbacks are 'manipulation' or opportune entry points, given AMD's strong position in the expanding AI sector.

Greenwich LifeSciences, Inc. engages in the development of a breast cancer immunotherapy designed to prevent the recurrence of breast cancer following surgery. The company was founded by Eric Rothe on August 29, 2006 and is headquartered in Stafford, TX.

Greenwich LifeSciences Inc

Greenwich LifeSciences is trending due to recent FDA clearance for commercial GP2 supply and confirmation of funding through 2026, significantly de-risking its late-stage breast cancer immunotherapy. The community is buzzing about two abstracts accepted for the upcoming AACR meeting, with high insider ownership fueling speculation for a potential partnership or buyout.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

$OKYO 

Neuropathic corneal pain represents one of the most debilitating and underserved areas in ophthalmology,” Dr Mantelli said in a statement. “OKYO Pharma’s focus on differentiated, mechanism-based approaches to inflammatory eye diseases and neuropathic corneal pain resonates strongly with my career-long dedication to translating breakthrough science into approved innovative therapies.”

In his new role, Dr Mantelli will oversee OKYO’s clinical development strategy, including advancing urcosimod in planned trials for NCP and other orphan indications. The company recently received FDA alignment on its proposed Phase 2b/3 study design and was granted fast-track designation and compassionate use authorization for urcosimod in NCP. OKYO expects to initiate a roughly 150-subject multiple-dose Phase 2b/3 study in the first half of 2026.

Very Exciting Times Ahead !!!!

StockTwits for iOS

Pharma Limited

 

Neuropathic corneal pain represents one of the most debilitating and underserved areas in ophthalmology,” Dr Mantelli said in a statement. “OKYO Pharma’s focus on differentiated, mechanism-based approaches to inflammatory eye diseases and neuropathic corneal pain resonates strongly with my career-long dedication to translating breakthrough science into approved innovative therapies.”

In his new role, Dr Mantelli will oversee OKYO’s clinical development strategy, including advancing urcosimod in planned trials for NCP and other orphan indications. The company recently received FDA alignment on its proposed Phase 2b/3 study design and was granted fast-track designation and compassionate use authorization for urcosimod in NCP. OKYO expects to initiate a roughly 150-subject multiple-dose Phase 2b/3 study in the first half of 2026.

Very Exciting Times Ahead !!!!